Global Trigeminal Neuralgia Treatment Market Is Estimated To Witness Significant Growth Owing To Growing Geriatric Population And Rising Disposable Income

Trigeminal Neuralgia Treatment Market

Overview:

There is no known cure for trigeminal neuralgia, whereas doctor may recommend medicine to control the pain. These drugs, usually carbamazepine (Tegretol) or oxcarbazepine (Trileptal), can relieve pain and some of the side effects. Medications alone aren't always enough, so doctors may refer to a specialist for surgery or other treatments. There are a number of options, including surgical procedures called microvascular decompression and radiofrequency thermal lesioning, or Botox injections.

A rhizotomy is an outpatient procedure in which the surgeon inserts a long needle through the skin on the side of the face affected by trigeminal neuralgia and injects a chemical or heat to deaden the pain fibers of the trigeminal nerve. This can help reduce the frequency of attacks. The most common surgical option for treating trigeminal neuralgia is neuroablative surgery, which is done by moving or removing blood vessels that are causing the nerve to malfunction. This is the best chance for relieving pain. Other procedures to treat trigeminal neuralgia include radiofrequency thermal lesioning, which uses heat to destroy part of the nerve that causes the pain. This procedure is used less often than other procedures.

Market Dynamics:

Growing product approvals are estimated to augment growth of the global Trigeminal Neuralgia Treatment Market during the forecast period. For instance, Basimglurant has gained Fast Track designation from the Food and Drug Administration for managing pain associated with trigeminal neuralgia, in October 2022. It is a potent inhibitor of metabotropic glutamate receptor 5 that has shown to be overexpressed during chronic pain. Moreover, growing side effects are anticipated to restrain growth of the global trigeminal neuralgia treatment for market during the forecast period.

Impact of COVID-19:

COVID-19 was announced as a global public health emergency in 2020 by the World Health Organization. The pandemic had long-term effects on the growth of several industries. The pandemic also affected the healthcare sector in many nations. Several nations were facing shortages of drugs and medical supplies. Strict restrictions were imposed in many countries to prevent the spread of the virus. 

These restrictions led to shortage of resources for conducting research and developmental activities and carrying out treatments for other chronic diseases. Several hospitals were prioritizing COVID-19 patients and other patients were being monitored remotely. This had a negative impact on the growth of the global Trigeminal Neuralgia Treatment Market.

Key Takeaways:

The global Trigeminal Neuralgia Treatment Market is expected to witness high growth, exhibiting CAGR of 7.81 % over the forecast period, due to increasing research and developmental activities.

For instance, investigational new drug application for phase 2b clinical trial of the mGLuR5 inhibitor NOE-101 has been authorized by the FDA in March 2022. The drug was found to be well-tolerated and safe in previous study.

North America is anticipated to witness significant growth in the global Trigeminal Neuralgia Treatment Market during the forecast period, owing to rising incidences of neuralgia and growing presence of key players.

Key players active in the global trigeminal neuralgia treatment for market are Lundbeck Pharmaceuticals LLC, GlaxoSmithKline PLC, Cadila Healthcare Limited, Pfizer Inc., Biogen, and Novartis AG.